ReviewFrontiers in immunology2013
Dendritic cell subsets in type 1 diabetes: friend or foe?
Review in Frontiers in immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 46 citations in OpenAlex.
- Mechanism of Action of OralVaccines · 2024Article
- HAMSAB diet ameliorates dysfunctional signaling in pancreatic islets in autoimmune diabetes.iScience · 2024Article
- Lower percentages of natural killer cells in children with type 1 diabetes and their siblings.Pediatric endocrinology, diabetes, and metabolism · 2023Article
- Review
- A Comprehensive Review of the Evolution of Insulin Development and Its Delivery Method.Pharmaceutics · 2022Review
- Dendritic Cells and Their Immunotherapeutic Potential for Treating Type 1 Diabetes.International journal of molecular sciences · 2022Review
- Fluorine MR Imaging Probes Dynamic Migratory Profiles of Perfluorocarbon-Loaded Dendritic Cells After Streptozotocin-Induced Inflammation.Molecular imaging and biology · 2022Article
- How dysregulation of the immune system promotes diabetes mellitus and cardiovascular risk complications.Frontiers in cardiovascular medicine · 2022Review
- Altered Frequency and Phenotype of HLA-G-Expressing DC-10 in Type 1 Diabetes Patients at Onset and in Subjects at Risk to Develop the Disease.Frontiers in immunology · 2021Article
- The modulation of mature dendritic cells from patients with type 1 diabetes using human periodontal ligament stem cells. An in-vitro study.Journal of diabetes and metabolic disorders · 2020Article
- Clinical Use ofFrontiers in immunology · 2020Review
- LPS enhances CTB-INSULIN induction of IDO1 and IL-10 synthesis in human dendritic cells.Cellular immunology · 2019Article
- Neutrophil Cytosolic Factor 1 in Dendritic Cells Promotes Autoreactive CD8Frontiers in immunology · 2019Article
- Review
- Considerations on the harvesting site and donor derivation for mesenchymal stem cells-based strategies for diabetes.CellR4-- repair, replacement, regeneration, & reprogramming · 2017Article
- The Role of Dendritic Cell Maturation in the Induction of Insulin-Dependent Diabetes Mellitus.Frontiers in immunology · 2017Review
- The Proteasome Inhibitor Bortezomib Controls Indoleamine 2,3-Dioxygenase 1 Breakdown and Restores Immune Regulation in Autoimmune Diabetes.Frontiers in immunology · 2017Article
- Peripheral Autoimmune Regulator Induces Exhaustion of CD4Frontiers in immunology · 2017Article
- Unique Features of Pancreatic-Resident Regulatory T Cells in Autoimmune Type 1 Diabetes.Frontiers in immunology · 2017Review
- Flow cytometric gating for spleen monocyte and DC subsets: differences in autoimmune NOD mice and with acute inflammation.Journal of immunological methods · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 1 diabetes (T1D) is a T cell mediated autoimmune disease characterized by immune mediated destruction of the insulin-producing β cells in the islets of Langerhans. Dendritic cells (DC) have been implicated in the pathogenesis of T1D and are also used as immunotherapeutic agents. Plasmacytoid (p)DC have been shown to have both protective and pathogenic effects and a newly described merocytic DC population has been shown to break tolerance in the mouse model of T1D, the non-obese diabetic (NOD) mouse. We have used DC populations to prevent the onset of T1D in NOD mice and clinical trials of DC therapy in T1D diabetes have been initiated. In this review we will critically examine the recent published literature on the role of DC subsets in the induction and regulation of the autoimmune response in T1D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.